Smoldering multiple myeloma requiring treatment

Time for a new definition?

Angela Dispenzieri, Alexander Keith Stewart, Asher A Chanan Khan, S Vincent Rajkumar, Robert A. Kyle, Rafael Fonseca, Prashant Kapoor, Peter Leif Bergsagel, Arleigh McCurdy, Morie Gertz, Martha Lacy, John A. Lust, Stephen J Russell, Steven R. Zeldenrust, Craig Reeder, Vivek Roy, Francis Buadi, David M Dingli, Suzanne R. Hayman, Nelson Leung & 3 others Yi Lin, Joseph R Mikhael, Shaji K Kumar

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active multiple myeloma (MM). Until recently, no interventional study in patients with SMM showed improved overall survival (OS) with therapy as compared with observation. A report from the PETHEMA-GEM (Programa Español de Tratamientos en Hematologica) group described both fewer myelomarelated events and better OS among patients with high-risk SMM who were treated with lenalidomide and dexamethasone. This unique study prompted us to review current knowledge about SMM and address the following questions: (1) Are there patients currently defined as SMM who should be treated routinely? (2) Should the definitions of SMM and MM be reconsidered? (3) Has the time come when not treating is more dangerous than treating? (4) Could unintended medical harm result from overzealous intervention? Our conclusion is that those patients with the highest-risk SMM (extreme bone marrow plasmacytosis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detected only by modern imaging) should be reclassified as active MM so that they can receive MM-appropriate therapy and the paradigm of careful observation for patients with SMM can be preserved.

Original languageEnglish (US)
Pages (from-to)4172-4181
Number of pages10
JournalBlood
Volume122
Issue number26
DOIs
StatePublished - Dec 19 2013

Fingerprint

Multiple Myeloma
Bone
Air cushion vehicles
Dexamethasone
Immunoglobulins
Imaging techniques
Therapeutics
Observation
Monoclonal Gammopathy of Undetermined Significance
Immunoglobulin Light Chains
Survival
lenalidomide
Bone Marrow

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Smoldering multiple myeloma requiring treatment : Time for a new definition? / Dispenzieri, Angela; Stewart, Alexander Keith; Chanan Khan, Asher A; Rajkumar, S Vincent; Kyle, Robert A.; Fonseca, Rafael; Kapoor, Prashant; Bergsagel, Peter Leif; McCurdy, Arleigh; Gertz, Morie; Lacy, Martha; Lust, John A.; Russell, Stephen J; Zeldenrust, Steven R.; Reeder, Craig; Roy, Vivek; Buadi, Francis; Dingli, David M; Hayman, Suzanne R.; Leung, Nelson; Lin, Yi; Mikhael, Joseph R; Kumar, Shaji K.

In: Blood, Vol. 122, No. 26, 19.12.2013, p. 4172-4181.

Research output: Contribution to journalArticle

@article{e18ec0b838464fd281c5845adddf3cbc,
title = "Smoldering multiple myeloma requiring treatment: Time for a new definition?",
abstract = "Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active multiple myeloma (MM). Until recently, no interventional study in patients with SMM showed improved overall survival (OS) with therapy as compared with observation. A report from the PETHEMA-GEM (Programa Espa{\~n}ol de Tratamientos en Hematologica) group described both fewer myelomarelated events and better OS among patients with high-risk SMM who were treated with lenalidomide and dexamethasone. This unique study prompted us to review current knowledge about SMM and address the following questions: (1) Are there patients currently defined as SMM who should be treated routinely? (2) Should the definitions of SMM and MM be reconsidered? (3) Has the time come when not treating is more dangerous than treating? (4) Could unintended medical harm result from overzealous intervention? Our conclusion is that those patients with the highest-risk SMM (extreme bone marrow plasmacytosis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detected only by modern imaging) should be reclassified as active MM so that they can receive MM-appropriate therapy and the paradigm of careful observation for patients with SMM can be preserved.",
author = "Angela Dispenzieri and Stewart, {Alexander Keith} and {Chanan Khan}, {Asher A} and Rajkumar, {S Vincent} and Kyle, {Robert A.} and Rafael Fonseca and Prashant Kapoor and Bergsagel, {Peter Leif} and Arleigh McCurdy and Morie Gertz and Martha Lacy and Lust, {John A.} and Russell, {Stephen J} and Zeldenrust, {Steven R.} and Craig Reeder and Vivek Roy and Francis Buadi and Dingli, {David M} and Hayman, {Suzanne R.} and Nelson Leung and Yi Lin and Mikhael, {Joseph R} and Kumar, {Shaji K}",
year = "2013",
month = "12",
day = "19",
doi = "10.1182/blood-2013-08-520890",
language = "English (US)",
volume = "122",
pages = "4172--4181",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - Smoldering multiple myeloma requiring treatment

T2 - Time for a new definition?

AU - Dispenzieri, Angela

AU - Stewart, Alexander Keith

AU - Chanan Khan, Asher A

AU - Rajkumar, S Vincent

AU - Kyle, Robert A.

AU - Fonseca, Rafael

AU - Kapoor, Prashant

AU - Bergsagel, Peter Leif

AU - McCurdy, Arleigh

AU - Gertz, Morie

AU - Lacy, Martha

AU - Lust, John A.

AU - Russell, Stephen J

AU - Zeldenrust, Steven R.

AU - Reeder, Craig

AU - Roy, Vivek

AU - Buadi, Francis

AU - Dingli, David M

AU - Hayman, Suzanne R.

AU - Leung, Nelson

AU - Lin, Yi

AU - Mikhael, Joseph R

AU - Kumar, Shaji K

PY - 2013/12/19

Y1 - 2013/12/19

N2 - Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active multiple myeloma (MM). Until recently, no interventional study in patients with SMM showed improved overall survival (OS) with therapy as compared with observation. A report from the PETHEMA-GEM (Programa Español de Tratamientos en Hematologica) group described both fewer myelomarelated events and better OS among patients with high-risk SMM who were treated with lenalidomide and dexamethasone. This unique study prompted us to review current knowledge about SMM and address the following questions: (1) Are there patients currently defined as SMM who should be treated routinely? (2) Should the definitions of SMM and MM be reconsidered? (3) Has the time come when not treating is more dangerous than treating? (4) Could unintended medical harm result from overzealous intervention? Our conclusion is that those patients with the highest-risk SMM (extreme bone marrow plasmacytosis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detected only by modern imaging) should be reclassified as active MM so that they can receive MM-appropriate therapy and the paradigm of careful observation for patients with SMM can be preserved.

AB - Smoldering multiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mostly premalignant disorder) and active multiple myeloma (MM). Until recently, no interventional study in patients with SMM showed improved overall survival (OS) with therapy as compared with observation. A report from the PETHEMA-GEM (Programa Español de Tratamientos en Hematologica) group described both fewer myelomarelated events and better OS among patients with high-risk SMM who were treated with lenalidomide and dexamethasone. This unique study prompted us to review current knowledge about SMM and address the following questions: (1) Are there patients currently defined as SMM who should be treated routinely? (2) Should the definitions of SMM and MM be reconsidered? (3) Has the time come when not treating is more dangerous than treating? (4) Could unintended medical harm result from overzealous intervention? Our conclusion is that those patients with the highest-risk SMM (extreme bone marrow plasmacytosis, extremely abnormal serum immunoglobulin free light chain ratio, and multiple bone lesions detected only by modern imaging) should be reclassified as active MM so that they can receive MM-appropriate therapy and the paradigm of careful observation for patients with SMM can be preserved.

UR - http://www.scopus.com/inward/record.url?scp=84891335728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891335728&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-08-520890

DO - 10.1182/blood-2013-08-520890

M3 - Article

VL - 122

SP - 4172

EP - 4181

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -